Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: International Council for Harmonisation guideline E2C | Statement: [ICH E2C, abbreviationOf, International Council for Harmonisation guideline E2C]

Target entity: International Council for Harmonisation guideline E2C
Context triple: [ICH E2C, abbreviationOf, International Council for Harmonisation guideline E2C]

• A. ICH E8 General Considerations for Clinical Trials
  ICH E8 General Considerations for Clinical Trials is an international guideline that outlines fundamental principles and quality considerations for the design, conduct, and evaluation of clinical studies across all phases of drug development.
• B. ICH E9 Statistical Principles for Clinical Trials
  ICH E9 Statistical Principles for Clinical Trials is an international guideline that defines key statistical concepts and methodologies to ensure the design, analysis, and interpretation of clinical trial data are scientifically sound and regulatory compliant.
• C. ICH E6 Good Clinical Practice
  ICH E6 Good Clinical Practice is an international ethical and scientific quality standard that governs the design, conduct, recording, and reporting of clinical trials involving human subjects.
• D. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• E. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: International Council for Harmonisation guideline E2C
Target entity description: International Council for Harmonisation guideline E2C is a regulatory framework that provides standardized requirements for the ongoing safety evaluation and periodic benefit-risk assessment of marketed medicinal products.

• A. ICH E8 General Considerations for Clinical Trials
  ICH E8 General Considerations for Clinical Trials is an international guideline that outlines fundamental principles and quality considerations for the design, conduct, and evaluation of clinical studies across all phases of drug development.
• B. ICH E9 Statistical Principles for Clinical Trials
  ICH E9 Statistical Principles for Clinical Trials is an international guideline that defines key statistical concepts and methodologies to ensure the design, analysis, and interpretation of clinical trial data are scientifically sound and regulatory compliant.
• C. ICH E6 Good Clinical Practice
  ICH E6 Good Clinical Practice is an international ethical and scientific quality standard that governs the design, conduct, recording, and reporting of clinical trials involving human subjects.
• D. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
  ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
• E. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• F. None of above. chosen